Introduction RaQualia was established in July 2008 with a mission to develop innovative medications that improve people's health and happiness. The company has transformed its R&D strategy to focus on core competencies in targeting ion channels for pain and gastrointestinal diseases. The company aims to enhance its drug discovery capabilities, improve shareholder value, and achieve financial stability through licensing activities and alliance management with corporate partners. RaQualia remains committed to providing patients with innovative medications as quickly as possible. |
Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Neoplasms | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Proteolysis-targeting chimeras (PROTAC) | 1 |
Hormone | 1 |
Target |
Mechanism P-CAB |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date05 Jul 2018 |
Target |
Mechanism EP4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism COX-2 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2016 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
RQ-00317076 ( COX-2 ) | Pain More | Phase 2 |
Grapiprant ( EP4 ) | Non-Small Cell Lung Cancer More | Phase 2 |
RQ-00434739 ( TRPM8 ) | Chronic Pain More | Phase 1 |
FIM-001 ( IRAK3 ) | Non-Small Cell Lung Cancer More | Preclinical |
RQ-00490721 ( CRHR2 ) | Heart Failure More | Preclinical |